Home' Australasian BioTechnology : Vol 28 No 1 Contents Australasian BioTechnology | Volume 28 | Number 1
MediGroup EBI is a privately owned Australian enterprise that launches niche, groundbreaking medical devices. In
Australia and New Zealand, products it exclusively supplies include: Exablate (using MRI-guided, focal ultrasound
to perform surgery and also control the blood–brain barrier); accident and emergency, and MedXpert ranges
of titanium reconstruction prosthetic implants; and other capital equipment and consumables used in operating
theatres. MediGroup EBI also exports, including to the United States, and is keen to engage with technology
partners seeking an Australia-based enterprise with early-stage marketing, trial and commercialisation expertise.
MediGroup EBI is the proud winner of the 2015 and 2016 Kerrin Rennie Awards for Excellence in Medical
Technology awarded by the Medical Technology Association of Australia.
T: 1300 362 534 | E: firstname.lastname@example.org
Materialise incorporates 27 years of 3D printing experience and has pioneered many of the leading medical
applications of 3D printing, enabling researchers, engineers and clinicians to revolutionise innovative patient-
specific treatment that helps improve and save lives. Materialise’s open and flexible platform of software and
services forms the foundation of certified medical 3D printing, in clinical as well as research environments, offering
virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants.
E: email@example.com | W: www.materialise.com/en/medical
Marken specialises in high-touch, personalised logistics for clinical trial materials and sensitive drug shipments
worldwide. As the clinical supply chain subsidiary of UPS and the only patient-centric supply chain organisation
that is 100 per cent dedicated to life sciences and pharmaceutical industries, Marken operates a global network of
clinical supply-chain services and depots to meet the increasingly complex demands of clients, with no geographic
Ryan Kafoure, Business Development Director – ANZ
T: 0423 882 442 | E: firstname.lastname@example.org | W: www.marken.com
Immutep is an Australian biotechnology company developing novel immunotherapy treatments for cancer and
autoimmune diseases, with operations in Europe, Australia and the United States. Its lead product, eftilagimod
alpha, is a LAG-3 product candidate that is currently in multiple clinical trials, including a Phase IIB trial in
combination with chemotherapy to boost the immune system response in cancer. Immutep is listed on the
Australian Stock Exchange (IMM) and on the NASDAQ (IMMP).
E: email@example.com | W: www.immutep.com
Lucid Health Consulting Pty Ltd
Lucid Health Consulting was founded in 2016 by the three directors, George Papadopoulos, Michael Aristides
and Steve Crowley, each with over 25 years of experience across pricing, reimbursement, health economics
and market access. The company specialises in health technology assessment for reimbursement and submission
preparation; pricing strategy, including negotiations and price defence; and market access, including advisory
boards, commercial assessments and stakeholder mapping.
George Papadopoulos, Director and Partner
T: +61 435 934 394 | E: firstname.lastname@example.org | L: /www.linkedin.com/in/gpapadopoulos/ | W: www.lucidhealthcon.com
Next ScienceTM pioneers innovative, proprietary technologies to address the problem of biofilm. With proven,
experienced management and scientific leadership, Next Science and its partners deliver breakthrough solutions
that see beyond the current limits imposed by powerful bacterial colonies. Next Science offers a new solution to
the biofilm problem with a proprietary, non-toxic technology that disrupts the biofilm’s extracellular polymeric
substance (EPS) matrix and, unlike competitors, offers no opportunity for bacterial resistance.
Byron Darroch, Executive VP, Global, Next Science
email@example.com | www.nextscience.com
Links Archive Vol 27 No 3 Vol 28 No 2 Navigation Previous Page Next Page